The Conversation (0)
Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
Mar. 20, 2018 09:09AM PST
Pharmaceutical InvestingInovio Pharmaceuticals (NASDAQ:INO) today announced it has closed an agreement providing ApolloBio Corp. (NEEQ:430187) with the exclusive right to develop, manufacture and commercialize VGX-3100, Inovio’s DNA immunotherapy product designed to treat precancers caused by human papillomavirus (HPV), within Greater China (mainland China, Hong Kong, Macao, Taiwan). As quoted in the press release: Dr. J. Joseph …
Inovio Pharmaceuticals (NASDAQ:INO) today announced it has closed an agreement providing ApolloBio Corp. (NEEQ:430187) with the exclusive right to develop, manufacture and commercialize VGX-3100, Inovio’s DNA immunotherapy product designed to treat precancers caused by human papillomavirus (HPV), within Greater China (mainland China, Hong Kong, Macao, Taiwan).
As quoted in the press release:
Dr. J. Joseph Kim, Inovio’s President and Chief Executive Officer, said, “We are pleased to close this agreement that opens large markets and brings us $23 million in non-dilutive cash with future milestone payments and royalties on sales. ApolloBio is an excellent partner that will provide significant capabilities and expertise relating to product development, the Chinese regulatory landscape, and the commercial market in China. This agreement strengthens and expands our global efforts to develop VGX-3100.”
